Period:
Draw Mode:
| Volume | 18,289 |
|
|||||
| News | - | ||||||
| Day High | 7.15 | Low High |
|||||
| Day Low | 6.72 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| INmune Bio Inc | INMB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.17 | -2.43% | 6.83 | 11:45:20 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.94 | 6.72 | 7.15 | 7.00 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 213 | 18,289 | $ 6.88 | $ 125,881 | - | 5.7501 - 11.258 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:45:20 | 2,000 | $ 6.83 | USD |
INmune Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 123.09M | 18.02M | - | 374k | -27.3M | -1.51 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
INmune Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INMB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.06 | 7.4456 | 6.55 | 6.80 | 42,209 | -0.23 | -3.26% |
| 1 Month | 8.06 | 8.3499 | 6.5001 | 7.21 | 53,676 | -1.23 | -15.26% |
| 3 Months | 11.00 | 11.258 | 6.5001 | 8.54 | 56,930 | -4.17 | -37.91% |
| 6 Months | 7.02 | 11.258 | 6.48 | 8.45 | 52,002 | -0.19 | -2.71% |
| 1 Year | 6.25 | 11.258 | 5.7501 | 7.99 | 52,374 | 0.58 | 9.28% |
| 3 Years | 11.00 | 30.37 | 4.6288 | 14.95 | 169,633 | -4.17 | -37.91% |
| 5 Years | 8.25 | 30.37 | 2.20 | 14.26 | 177,448 | -1.42 | -17.21% |
INmune Bio Description
| INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others. |